Logo image of RGNX

REGENXBIO INC (RGNX) Stock Fundamental Analysis

USA - NASDAQ:RGNX - US75901B1070 - Common Stock

12.575 USD
+0.27 (+2.24%)
Last: 10/16/2025, 12:01:54 PM
Fundamental Rating

4

RGNX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. The financial health of RGNX is average, but there are quite some concerns on its profitability. RGNX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RGNX has reported negative net income.
In the past year RGNX has reported a negative cash flow from operations.
RGNX had negative earnings in 4 of the past 5 years.
RGNX had negative operating cash flow in 4 of the past 5 years.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

RGNX's Return On Assets of -30.22% is fine compared to the rest of the industry. RGNX outperforms 66.98% of its industry peers.
RGNX has a Return On Equity (-82.17%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -30.22%
ROE -82.17%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

RGNX has a Gross Margin of 82.44%. This is amongst the best in the industry. RGNX outperforms 85.63% of its industry peers.
In the last couple of years the Gross Margin of RGNX has declined.
The Profit Margin and Operating Margin are not available for RGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RGNX has more shares outstanding
RGNX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.53, we must say that RGNX is in the distress zone and has some risk of bankruptcy.
RGNX has a Altman-Z score (-1.53) which is in line with its industry peers.
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.53
ROIC/WACCN/A
WACC9.36%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

RGNX has a Current Ratio of 3.13. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RGNX (3.13) is worse than 63.06% of its industry peers.
RGNX has a Quick Ratio of 3.13. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
RGNX has a Quick ratio of 3.13. This is in the lower half of the industry: RGNX underperforms 60.07% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.13
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.10% over the past year.
Looking at the last year, RGNX shows a very strong growth in Revenue. The Revenue has grown by 74.98%.
Measured over the past years, RGNX shows a quite strong growth in Revenue. The Revenue has been growing by 18.81% on average per year.
EPS 1Y (TTM)34.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.43%
Revenue 1Y (TTM)74.98%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%-4.2%

3.2 Future

RGNX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.48% yearly.
Based on estimates for the next years, RGNX will show a very strong growth in Revenue. The Revenue will grow by 47.45% on average per year.
EPS Next Y45.86%
EPS Next 2Y20.91%
EPS Next 3Y18.29%
EPS Next 5Y14.48%
Revenue Next Year173.54%
Revenue Next 2Y65.98%
Revenue Next 3Y60.52%
Revenue Next 5Y47.45%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RGNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

RGNX's earnings are expected to grow with 18.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.91%
EPS Next 3Y18.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RGNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGENXBIO INC

NASDAQ:RGNX (10/16/2025, 12:01:54 PM)

12.575

+0.27 (+2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/amc
Inst Owners87.21%
Inst Owner Change0.27%
Ins Owners7.16%
Ins Owner Change1.09%
Market Cap635.16M
Analysts84.21
Price Target31.86 (153.36%)
Short Float %10.87%
Short Ratio8.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.31%
Min EPS beat(2)-75.63%
Max EPS beat(2)-22.99%
EPS beat(4)1
Avg EPS beat(4)-21.8%
Min EPS beat(4)-75.63%
Max EPS beat(4)13.65%
EPS beat(8)3
Avg EPS beat(8)-8.99%
EPS beat(12)4
Avg EPS beat(12)-9.5%
EPS beat(16)5
Avg EPS beat(16)-8.41%
Revenue beat(2)0
Avg Revenue beat(2)-19.97%
Min Revenue beat(2)-25.51%
Max Revenue beat(2)-14.42%
Revenue beat(4)1
Avg Revenue beat(4)-12.95%
Min Revenue beat(4)-25.51%
Max Revenue beat(4)0.57%
Revenue beat(8)2
Avg Revenue beat(8)-14.89%
Revenue beat(12)2
Avg Revenue beat(12)-19.57%
Revenue beat(16)4
Avg Revenue beat(16)-14.02%
PT rev (1m)4.98%
PT rev (3m)-1.64%
EPS NQ rev (1m)-0.06%
EPS NQ rev (3m)-428.19%
EPS NY rev (1m)-44.5%
EPS NY rev (3m)-4256.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-77.61%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)-28.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.08
P/FCF N/A
P/OCF N/A
P/B 2.97
P/tB 2.97
EV/EBITDA N/A
EPS(TTM)-3.44
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS3.08
BVpS4.23
TBVpS4.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.22%
ROE -82.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.44%
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.8%
Cap/Sales 1.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3.13
Altman-Z -1.53
F-Score5
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)103.5%
Cap/Depr(5y)301.57%
Cap/Sales(3y)13.73%
Cap/Sales(5y)15.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.43%
EPS Next Y45.86%
EPS Next 2Y20.91%
EPS Next 3Y18.29%
EPS Next 5Y14.48%
Revenue 1Y (TTM)74.98%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%-4.2%
Revenue Next Year173.54%
Revenue Next 2Y65.98%
Revenue Next 3Y60.52%
Revenue Next 5Y47.45%
EBIT growth 1Y33.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year87.66%
EBIT Next 3Y20.6%
EBIT Next 5Y18.2%
FCF growth 1Y61.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.69%
OCF growth 3YN/A
OCF growth 5YN/A